# Adimab

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/adimab

- Industry: Biotechnology
- Headquarters: Lebanon, US
- Website: www.adimab.com
- Total disclosed funding: $40M
- Latest round: Series F (Mar 16, 2012)
- Investors on record: 5

## About

Adimab, LLC is a biotechnology company focused on biologics discovery and engineering, specializing in the development of antibodies and multispecific therapeutics through innovative yeast-based platforms.Founded in 2007 in Lebanon, US, Adimab, LLC specializes in biologics discovery, particularly in antibody development. The company has not undergone any significant pivots or changes in its fundamental operations. Co-founded by Errik Anderson, Karl Wittrup, and Tillman Gerngross, it has raised a total of USD 13.8 mn through 6 funding deals, with the most recent being a Series F round in April 2012, where investors included GV, Polaris Partners, and SV Health Investors. The company operates primarily from the US and Europe.Adimab specializes in biologics discovery and engineering, focusing on the development of antibodies and multispecific therapeutics. Utilizing a proprietary yeast-based platform, the company creates a diverse range of therapeutic candidates including IgGs, single domain antibodies (HCAbs), and multispecific leads. Targeting various therapeutic areas such as oncology, autoimmune disorders, and infectious diseases, Adimab has advanced over 600 therapeutic programs, partnering with pharmaceutical and biotechnology companies to integrate its technology into their drug discovery processes.Adimab generates revenue primarily through strategic partnerships and collaborations with pharmaceutical and biotech companies. These collaborations involve funding for specific projects in exchange for access to Adimab's proprietary technology and the resulting therapeutic candidates. Revenue also comes from milestone payments related to projects as they progress. Although specific financial arrangements are kept private, these relationships typically include agreements outlining financial terms based on project milestones and royalty structures.Adimab aims to innovate its product offerings by advancing its current platform for generating multispecific therapeutics, with no specific launch dates provided. The firm is looking to expand its reach within the US and into key European markets by leveraging its existing partnerships. The recent Series F funding of USD 13.8 mn will be utilized to support these growth initiatives, ensuring that the company effectively scales its operations and develops new therapeutic candidates.

## Funding rounds

- Series F, Mar 16, 2012, $14M — Polaris Partners, SV Health Investors, GV
- Series E, Nov 22, 2010, $4M — Polaris Partners, GV
- Series D, Jan 22, 2010, $8.2M — OrbiMed Advisors, Polaris Partners, SV Health Investors, Borealis Ventures, GV
- Series C, Nov 20, 2008, $4M — OrbiMed Advisors, Polaris Partners, SV Health Investors, Borealis Ventures
- Series B, Mar 14, 2008, $3.2M — Polaris Partners, SV Health Investors
- Series A, Aug 27, 2007, $6.3M — Polaris Partners, SV Health Investors

## Investors

- Polaris Partners (https://capitalatlas.ai/funds/polaris-partners) — Series A, Series B, Series C, Series D, Series E, Series F
- SV Health Investors (https://capitalatlas.ai/funds/sv-health-investors) — Series A, Series B, Series C, Series D, Series F
- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series C, Series D
- Borealis Ventures (https://capitalatlas.ai/funds/borealis-ventures) — Series C, Series D
- GV (https://capitalatlas.ai/funds/gv) — Series D, Series E, Series F